Adverse drug reactions from psychotropic medicines in the paediatric population: Analysis of reports to the Danish Medicines Agency over a decade

BMC Research Notes

Volumn 3, Issue , 2010, Pages

  Aagaard, Lise ^a,b   Hansen, Ebba H ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954547549     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-3-176     Document Type: Article

References (17)

1. Meeting highlights from the Committee for Medicinal Products for Human Use (EMEA/431407/2007). http://www.emea.europa.eu/pdfs/human/press/pr/ 43140707en.pdf [Accessed 18 February 2010]
2. European Medicines Agency makes recommendations for safer use of Ritalin and other methylphenidate-containing medicines in the EU (EMEA/22315/2009). http://www.ema.europa.eu/pdfs/human/referral/methylphenidate/2231509en.pdf [Accessed 18 February 2010]
3. Paediatric prescribing practices and the FDA Black-box warning on antidepressants. A Cheung D Sacks CS Dewa J Pong A Levitt, J Dev Behav Pediatr 2008 29 213 15 10.1097/DBP.0b013e31817bd7c9 18550990
4. Information about adverse drug reactions reported in children: a qualitative review of empirical studies. L Aagaard AC Christensen EH Hansen, Br J Clin Pharmacol 2010 20233206
5. Facing the evidence: antidepressant treatment in children and adolescents. EJ Garland, CMAJ 2004 170 489 91 14970097
6. Paediatric psychopharmacology: problems and prospects. MA Riddle MJ Labellarte JT Walkup, J Child Adolesc Psychopharmacol 1998 8 87 97 10.1089/cap.1998.8.87 9730074
7. The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. A Neubert H Dormann J Weiss T Egger M Criegee-Rieck W Rascher K Brune B Hinz, Drug Saf 2004 27 1059 67 10.2165/00002018-200427130- 00006 15471510
8. Opening the white boxes: The licensing documentation of efficacy and safety of psychotropic medicines for children. L Aagaard S Thirstrup EH Hansen, Pharmacoepidemiol Drug Saf 2009 18 401 11 10.1002/pds.1735 19326364
9. Structures and processes in spontaneous reporting systems: a comparative study of Australia and Denmark. L Aagaard DI Stenver EH Hansen, Pharm World Sci 2008 30 563 70 10.1007/s11096-008-9210-y 18350372
10. Adverse drug reactions in the paediatric population in Denmark: a retrospective analysis of reports made to the Danish Medicines Agency from 1998 to 2007. L Aagaard CB Weber EH Hansen, Drug Saf 2010 33 327 29 10.2165/11319100-000000000-00000 20297864
11. Paediatric adverse drug reaction reporting: understanding and future directions. BC Carleton MA Smith MN Gelin SC Heathcote, Can J Clin Pharmacol 2007 14 45 e57 17297195
12. SSRI use during pregnancy is associated with fetal abnormalities. R Dobson, BMJ 2006 333 824
13. Maternal Use of Selective Serotonin Reuptake Inhibitors and Risk of Congenital Malformations. P Wogelius M Nørgaard M Gislum L Pedersen E Munk PB Mortensen L Lipworth HT Sørensen, Epidemiology 2006 17 701 4 10.1097/01.ede.0000239581.76793.ae 17028507
14. Safety of selective serotonin reuptake inhibitors in pregnancy. DC Cuevas EJ Sanz, Curr Drug Saf 2006 1 17 24 10.2174/157488606775252593 18690911
15. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. N Lund LH Pedersen TB Henriksen, Arch Pediatr Adolesc Med 2009 163 949 54 10.1001/archpediatrics.2009.164 19805715
16. Technology assessment in a user perspective- experiences with drug technology. EH Hansen, Int J Techn Assess Health Care 1992 8 150 65 10.1017/S0266462300008011
17. Information about adverse drug reactions explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics, SSRIs and NSAIDs. L Aagaard EH Hansen, BMC Pharmacology 2009 9 4 19284552